3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Lung Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Carcinoma
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
Adenocarcinoma
1
ALK-positive NSCLC
1
Interventions
Oxaliplatin
10
Fluorouracil
7
Leucovorin
6
Gemcitabine
6
Docetaxel
6
Capecitabine
6
Paclitaxel
5
Cisplatin
5
zolbetuximab
4
Ramucirumab
3
Pemetrexed
3
Drug Therapy
3
Carboplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
regorafenib
2
pembrolizumab
2
Vinorelbine
2
Surgical Procedures, Operative
2
Radiotherapy
2
Nivolumab
2
Neoadjuvant Therapy
2
Cyclophosphamide
2
Chemoradiotherapy
2
Bevacizumab
2
Afatinib
2
vandetanib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Adenocarcinoma
×
Crizotinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA